Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is a Healthcare company (Biotechnology) with a market capitalization of $230M. The Maz Rating grades it against the other companies in its sector.
Vanda Pharmaceuticals Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.81, Vanda Pharmaceuticals Inc. trades at 1.0x sales and 1.2x book value. Over the last twelve months it generated about $228M of revenue and a net loss of $278M. It runs a gross margin of 92.7%, an operating margin of -77.6% and a net margin of -119.9%. It shows return on equity of -106.9%, return on invested capital of -76.7% and a free cash flow yield of -82.6%. On the balance sheet: a debt-to-equity ratio of 0.11 and a current ratio of 1.54. Over the past 52 weeks the share price ranged from $3.57 to $9.94, with a beta of 0.73.
Vanda Pharmaceuticals Inc. does not currently pay a dividend.
19 Wall Street analyst ratings cover the stock: 13 Buy, 5 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Vanda Pharmaceuticals Inc. (VNDA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 1.66% / 30% · (Cash+Inv) / Mkt Cap (36m) 49.9% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 1.66% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 49.9% / 33% · Receivables / Mkt Cap (36m) 21.4% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 1.66% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 49.9% / 33.33% · Receivables / Mkt Cap (24m) 21.4% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.27% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 45.2% / 33.33% · Receivables / Avg Assets (4Q) 13.5% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 1.22% / 33.33% · (Cash+ST Inv) / Total Assets 36.7% / 33.33% · (Cash+Recv) / Total Assets 52.5% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, Vanda Pharmaceuticals Inc. (VNDA) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Vanda Pharmaceuticals Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m).
Vanda Pharmaceuticals Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.